Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

• Type: Article in International Scientific Journal
• Date: 2019

Authors

Corremans, R (Author) Other; Adao, R (Author) Other; De Keulenaer, GW (Author) Other; Leite Moreira, AF (Author) Other; Brás-Silva C (Author) FMUP

Journal

Title: Clinical And Experimental Pharmacology And Physiology

Vol. 46

Pages: 204-215

ISSN: 0305-1870

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 36 Citations

Scopus - 43 Citations

Scientific classification

CORDIS: Health sciences

FOS: Medical and Health sciences

Other information

Authenticus ID: P-00P-TPV

DOI: 10.1111/1440-1681.13036

Abstract (EN): Anthracycline chemotherapy has a prominent role in treating many forms of cancer. Unfortunately, cardiotoxic side effects represent a serious limitation to their use, with doxorubicin being the leading drug of the group. Indeed, anthracycline-induced cardiomyopathy is an important public health concern because it may not be detected for many years and remains a lifelong threat. Even after decades of investigation, neither the exact mode of action of anthracyclines nor the pathways leading to their side effect are fully understood. It is increasingly important to establish collaboration between oncologists and cardiologists to improve the management of cancer patient receiving anthracyclines. This article reviews the clinical course, pathogenesis, cardiac monitoring and new concepts in diagnosing and preventing anthracycline-induced cardiotoxicity.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 12